Hurthle Cell Carcinoma Market Size, Share, Treatment Trends and Forecast 2035

Hurthle Cell Carcinoma Market Size and Forecast 2035

The global Hurthle cell carcinoma market is estimated at USD 90.0 million in 2025 and is forecast to reach USD 161.2 million by 2035, expanding at a CAGR of 6.0% during 2026–2035.

The existing DataM Intelligence report identifies a 6% growth trajectory, North America as the largest market and Asia-Pacific as the fastest-growing region, although its historical market values are still shown as placeholders.

Hurthle cell carcinoma is a rare differentiated thyroid malignancy. The American Thyroid Association estimates that it represents 3–5% of thyroid cancers. The disease is now increasingly referred to as oncocytic thyroid carcinoma, following changes in pathological classification. It differs clinically from conventional follicular thyroid carcinoma because it has a higher tendency toward recurrence outside the neck and is more resistant to radioactive iodine treatment.

The market is moving away from a treatment model centered primarily on thyroidectomy followed by empiric radioactive iodine. Surgery remains fundamental, but advanced treatment increasingly depends on disease progression, radioactive-iodine avidity, tumor location and molecular alterations that may enable targeted therapy.

Hurthle Cell Carcinoma Market Highlights

• 2025 Market Size: USD 90.0 Million
• 2035 Forecast Market Size: USD 161.2 Million
• CAGR, 2026–2035: 6.0%
• Largest Region: North America – 40.4% share
• Fastest-Growing Region: Asia-Pacific
• Leading Treatment Segment: Surgery – 36.4% share
• Highest-Value Disease Stage: Stage IV – 31.5% share

Hurthle Cell Carcinoma Market Definition

Hurthle cell carcinoma is a malignant oncocytic tumor arising from thyroid follicular cells. Under contemporary terminology it is commonly classified as oncocytic thyroid carcinoma.

The National Cancer Institute describes Hurthle cell carcinoma within differentiated thyroid cancer and notes that treatment generally follows principles used for follicular thyroid carcinoma. Surgery remains the principal treatment for primary localized disease.

The market covered in this report includes surgical management, postoperative radioactive iodine where clinically appropriate, thyroid-stimulating-hormone suppression, targeted systemic therapies for progressive or metastatic disease, local treatment for recurrent/metastatic lesions and emerging investigational therapies.

Papillary, medullary and anaplastic thyroid cancers are excluded unless a product's commercial revenue can be attributed specifically to eligible Hurthle/oncocytic thyroid carcinoma patients.

White-Space Opportunity: Hurthle-Specific Theranostics for RAI-Refractory Disease

The clearest emerging white-space opportunity is treatment designed specifically for metastatic Hurthle cell carcinoma that no longer responds to conventional radioactive iodine.

This is important because radioactive iodine is substantially less reliable in oncocytic thyroid cancer than in many other differentiated thyroid cancers. The 2025 American Thyroid Association framework now separately characterizes oncocytic thyroid cancer and specifically recognizes its greater resistance to RAI.

A new NIH-sponsored program is beginning to address this problem directly.

As of August 2026, the National Institutes of Health is preparing a study of ¹⁷⁷Lu-DOTA-EB-TATE in adults with metastatic, radioactive-iodine–non-responsive oncocytic/Hurthle-cell thyroid cancer.

The investigational radiopharmaceutical targets somatostatin receptors found at increased levels on selected tumor cells. The protocol plans four intravenous treatments separated by 8–12 weeks and specifically enrolls metastatic Hurthle cell carcinoma that has failed conventional radioactive iodine treatment.

This creates a potentially important new treatment category.

Current systemic therapy largely borrows from the wider radioactive-iodine–refractory differentiated thyroid cancer market. A successful Hurthle-specific radioligand therapy could instead create a disease-focused commercial segment with its own imaging, patient-selection and treatment pathway.

Hurthle Cell Carcinoma Market Key Takeaways

• The market is estimated at USD 90 million in 2025 and is forecast to reach USD 161.2 million by 2035.
• North America holds 40.4% of market revenue, maintaining the leadership position identified in the existing DataM Intelligence report.
• Surgery is estimated to account for 36.4% of the market, replacing radioactive iodine as the leading treatment category in the refreshed commercial model.
• The change is clinically important. The previous RD assigns radioactive iodine 38.5% market share, but current ATA guidance recognizes oncocytic thyroid cancer as more resistant to RAI than other differentiated thyroid cancers and supports more individualized postoperative decision-making.
• Targeted therapy is estimated to represent 27.8% of 2025 market value, making it the second-largest treatment category and the principal pharmaceutical growth segment.
• Stage IV disease represents an estimated 31.5% of treatment revenue despite a much smaller patient population than early-stage disease because metastatic RAI-refractory patients may require prolonged high-value systemic treatment.
• Asia-Pacific remains the fastest-growing major region. Its opportunity is supported by a large underlying thyroid-cancer population: Asia accounted for 77.4% of the 959,281 thyroid cancer cases estimated worldwide in 2024.

Hurthle Cell Carcinoma Industry Trends and Strategic Insights

The 2025 ATA Guidelines Change the Treatment Conversation

One of the most relevant recent changes for this market is the publication of the 2025 American Thyroid Association differentiated thyroid cancer guidelines.

The revised framework evaluates follicular and oncocytic thyroid cancers separately and introduces a more detailed four-level recurrence-risk structure: low risk, low-intermediate risk, intermediate-high risk and high risk.

The guidance is designed to improve decisions around additional therapy after surgery, including radioactive iodine.

For oncocytic thyroid carcinoma, this matters because treating every patient according to a generic differentiated-thyroid-cancer pathway can result in unnecessary therapy while failing to recognize patients at greater risk of distant recurrence.

Commercially, the trend favors risk-adapted treatment rather than routine maximal treatment.

Radioactive Iodine Is Becoming More Selective

Radioactive iodine remains relevant in Hurthle cell carcinoma, but its role is more nuanced than the previous RD suggests.

The American Thyroid Association describes Hurthle/oncocytic carcinoma as more resistant to RAI than other differentiated thyroid cancers. A large retrospective study summarized by ATA included 2,279 patients who underwent total thyroidectomy; 63% received postoperative RAI, but the analysis did not demonstrate a clear cancer-specific survival advantage after adjustment.

This does not mean RAI has no role.

Instead, the decision increasingly depends on recurrence risk, disease distribution, iodine avidity and postoperative findings.

The commercial implication is that RAI volume may grow more slowly than targeted therapy even as overall Hurthle cancer treatment expenditure increases.

Local Therapy Is Being Used to Delay Systemic Treatment

The 2025 ATA guidelines also place greater emphasis on local disease control before systemic therapy in selected patients with metastatic radioactive-iodine–refractory differentiated thyroid cancer.

The ATA notes that 5–15% of differentiated thyroid cancer patients develop more advanced disease that becomes RAI refractory and that tyrosine kinase inhibitors can produce substantial adverse-event burden. The updated approach therefore supports active surveillance, repeat surgery, focused radiation or radiofrequency ablation in suitable patients before beginning continuous systemic treatment.

This has particular relevance to Hurthle cell carcinoma because patients may live for years with slowly progressing metastatic disease.

The emerging commercial market is therefore not simply “RAI versus TKI.” It is an increasingly sequenced pathway combining local treatment and systemic therapy.

Lenvatinib Remains a Major Systemic Treatment Option

Lenvatinib is currently indicated for adults with locally recurrent or metastatic, progressive, radioactive-iodine–refractory differentiated thyroid cancer.

Its differentiated-thyroid-cancer label can include eligible oncocytic/Hurthle tumors.

Real-world evidence continues to support its role. A 2025 study examining lenvatinib across thyroid cancer pathological groups found continued activity in differentiated thyroid cancer, including patients in whom radioactive iodine was not feasible.

A Phase IV lenvatinib study in progressive RAI-refractory differentiated thyroid cancer completed primary follow-up in September 2025, with the trial record updated in March 2026.

The drug therefore remains one of the key commercial benchmarks for systemic treatment.

Cabozantinib Provides a Later-Line Option

For disease progressing after VEGFR-targeted treatment, cabozantinib expands the systemic pathway.

FDA approved cabozantinib for locally advanced or metastatic differentiated thyroid cancer that has progressed after prior VEGFR-targeted therapy in patients who are ineligible for or refractory to RAI.

In COSMIC-311, median progression-free survival was 11.0 months with cabozantinib compared with 1.9 months with placebo.

This creates a sequential commercial model in which patients can move from one targeted therapy to another rather than exhausting systemic options after first-line TKI failure.

Molecular Profiling Is Creating Small but High-Value Treatment Niches

Genomic profiling is becoming increasingly relevant in advanced thyroid cancer.

Current precision targets include RET and NTRK gene fusions, among others.

Selpercatinib is currently labeled for adult and pediatric patients aged two years and older with advanced or metastatic thyroid cancer carrying a RET fusion who require systemic therapy and are RAI refractory when RAI is appropriate.

Larotrectinib is approved for adults and children with NTRK fusion-positive solid tumors meeting the relevant advanced-disease criteria. Its prescribing information was updated in April 2025.

Entrectinib provides another tumor-agnostic treatment route for eligible NTRK fusion-positive tumors.

RET and NTRK fusions are not present in most Hurthle carcinomas, but when actionable alterations occur, the value of comprehensive molecular profiling increases substantially.

A 2026 review of thyroid precision oncology describes the wider treatment paradigm as shifting from nonspecific multikinase inhibition toward molecularly matched and adaptively sequenced therapies.

Hurthle Cell Carcinoma Market Scope

Hurthle Cell Carcinoma Market Disruption Analysis

Three changes are reshaping the commercial treatment model.

The first is reclassification.

The disease was historically treated primarily as a variant of follicular carcinoma. Contemporary pathological classification increasingly uses the term oncocytic thyroid carcinoma and recognizes biologically meaningful differences. ATA notes that the World Health Organization recommended the oncocytic carcinoma terminology and that the disease displays more aggressive features than conventional follicular carcinoma.

The second disruption is reduced reliance on automatic postoperative RAI.

The 2025 ATA framework specifically recognizes greater RAI resistance in oncocytic thyroid cancer and emphasizes individualized recurrence-risk assessment.

The third is the emergence of targeted systemic and radioligand treatment for advanced disease.

Lenvatinib, cabozantinib and molecularly selected RET/NTRK inhibitors already provide systemic options within differentiated thyroid cancer. The NIH study of ¹⁷⁷Lu-DOTA-EB-TATE goes a step further by testing a treatment specifically in metastatic RAI-non-responsive oncocytic/Hurthle thyroid cancer.

If successful, disease-specific theranostics could create a new segment between conventional RAI and broad-spectrum kinase inhibition.

Hurthle Cell Carcinoma Market Dynamics

Increasing Thyroid Cancer Diagnosis Expands the Addressable Population

The global thyroid cancer burden continues to increase.

GLOBOCAN estimated 959,281 new thyroid cancer cases worldwide in 2024, making thyroid cancer the sixth most frequently diagnosed cancer in its latest global dataset.

The U.S. alone is expected to record 45,240 new thyroid cancer cases in 2026, according to SEER.

Hurthle/oncocytic carcinoma represents only a small fraction of these cases, but higher global detection naturally enlarges the pool of patients undergoing pathological evaluation and treatment.

Rarity Creates an Orphan-Oncology Opportunity

Hurthle cell carcinoma represents 3–5% of thyroid cancers.

This limits absolute patient volume but can make the indication attractive for highly specialized therapies.

Rare cancers often support commercially viable targeted products when treatment addresses a clearly defined high-risk population with limited alternatives.

The emerging ¹⁷⁷Lu-DOTA-EB-TATE program illustrates this possibility: it focuses specifically on metastatic Hurthle cancer that no longer responds to standard radioactive iodine.

RAI Resistance Drives Higher-Value Systemic Therapy

RAI-refractory disease is the strongest pharmaceutical revenue driver.

Once progressive metastatic disease is no longer effectively controlled by iodine-based treatment or local therapy, patients can enter prolonged systemic-treatment pathways involving VEGFR-targeted TKIs and, where relevant, molecularly selected drugs.

Current FDA labels support lenvatinib in progressive RAI-refractory DTC and cabozantinib after prior VEGFR-targeted treatment.

This creates higher treatment expenditure per advanced patient than conventional thyroid-hormone suppression or postoperative surveillance.

Molecular Testing Expands Treatment Optionality

The commercial relevance of molecular profiling grows as targeted treatment options increase.

A patient with a RET fusion may qualify for selpercatinib, while an NTRK fusion may create eligibility for tumor-agnostic TRK inhibition.

Testing therefore influences more than prognosis. It can determine which high-value therapy enters the treatment pathway.

Limited Patient Numbers Constrain Traditional Drug Development

The same rarity that creates orphan-drug opportunity also complicates clinical development.

Recruitment into Hurthle-specific randomized trials is difficult, and many systemic treatment data are derived from broader differentiated-thyroid-cancer populations.

This is why the NIH ¹⁷⁷Lu-DOTA-EB-TATE trial is notable: it is specifically designed around metastatic oncocytic/Hurthle thyroid cancer rather than thyroid cancer broadly.

Toxicity Can Delay the Start of TKIs

Systemic therapy is effective but not benign.

The 2025 ATA framework highlights that more than 90% of patients receiving TKIs in relevant differentiated-thyroid-cancer settings experience at least one adverse event. This contributes to the recommendation that local treatment or surveillance should be considered before systemic therapy in appropriate indolent metastatic disease.

This limits unnecessary drug exposure but also reinforces the importance of better-tolerated next-generation treatments.

Hurthle Cell Carcinoma Market Segment Analysis

Stage IV Generates 31.5% of Market Revenue

Stage IV disease is estimated to account for 31.5% of global Hurthle cell carcinoma treatment revenue in 2025, representing about USD 28.4 million.

Its revenue share is greater than its share of patients because metastatic disease can require prolonged systemic treatment, repeat imaging, focused local therapy and sequential TKIs.

Advanced Hurthle carcinoma can spread hematogenously, including to the lungs and bones, and can become resistant to iodine-based therapy. The NIH's current Hurthle-specific radiopharmaceutical trial is explicitly focused on metastatic, RAI-non-responsive disease, illustrating the remaining unmet need.

Stage I disease is estimated to contribute 24.8% of market value, Stage II about 22.6%, and Stage III 21.1%.

Earlier stages generate considerable treatment revenue through surgery and postoperative management, while later disease carries higher pharmaceutical expenditure per patient.

Surgery Leads with 36.4% Market Share

Surgery is estimated to represent 36.4% of Hurthle cell carcinoma treatment revenue in 2025, equivalent to roughly USD 32.8 million.

This differs materially from the existing DMI page, which places radioactive iodine at 38.5%.

NCI identifies surgery as the treatment of choice for primary differentiated thyroid tumors, including Hurthle carcinoma treated according to equivalent-stage follicular carcinoma principles.

The extent of surgery depends on tumor size, invasion, disease distribution, recurrence risk and the need for additional treatment.

The 2025 ATA framework has further strengthened individualized surgical and postoperative decision-making rather than a uniform total-thyroidectomy-plus-RAI strategy.

Targeted Therapy Accounts for 27.8%

Targeted therapy is estimated to represent 27.8% of market revenue in 2025, or USD 25.0 million, making it the second-largest treatment category.

Its share is high relative to patient numbers because systemic treatment is concentrated among recurrent, progressive and metastatic cases and involves relatively high-value medicines.

Lenvatinib remains a major first systemic option for progressive RAI-refractory differentiated thyroid cancer, while cabozantinib provides a treatment route following prior VEGFR-targeted therapy.

RET and NTRK inhibitors create additional precision subsegments for patients with actionable gene fusions.

Targeted therapy is expected to gain market share through 2035.

Radioactive Iodine Represents 18.6%

Radioactive iodine is estimated to hold 18.6% of market revenue in 2025, equal to around USD 16.7 million.

It remains an important treatment option for selected patients after thyroidectomy, but oncocytic tumors are less predictably iodine avid than conventional differentiated thyroid carcinoma.

ATA's 2025 guidance explicitly characterizes oncocytic thyroid cancer as more RAI resistant, while previous population analyses have produced conflicting findings regarding the survival benefit of postoperative RAI.

The market is therefore shifting from routine RAI toward risk- and uptake-based use.

Thyroid Hormone Therapy Holds 9.2%

Thyroid hormone therapy represents an estimated 9.2% of the 2025 market, around USD 8.3 million.

After thyroidectomy, patients generally require thyroid-hormone replacement. TSH suppression can also be incorporated into differentiated-thyroid-cancer management according to disease risk and treatment status. NCI includes thyroid-suppression therapy among treatment options for differentiated thyroid cancer.

Its revenue per patient is lower than targeted systemic treatment, but long treatment duration supports a recurring commercial contribution.

Immunotherapy and Emerging Therapies Remain Small but Strategically Relevant

Conventional immunotherapy accounts for an estimated 3.1% of the current market, while other treatments contribute 4.9%.

Checkpoint inhibition is not currently a routine disease-specific standard for most Hurthle carcinoma patients.

The more important innovation opportunity is emerging from targeted radionuclide treatment and molecularly selected therapy rather than nonspecific immunotherapy.

The NIH ¹⁷⁷Lu-DOTA-EB-TATE study could provide one of the first genuinely Hurthle-specific advanced treatment strategies if clinical activity is demonstrated.

Hospitals Account for 68.5% of Market Revenue

Hospitals are estimated to generate 68.5% of global treatment revenue in 2025.

Their dominance reflects thyroidectomy, radioactive iodine administration, molecular testing, management of metastatic disease and systemic therapy initiation.

Ambulatory surgical centers account for 19.6%, particularly through thyroid surgery in appropriately selected patients and healthcare systems.

Specialty oncology/endocrine practices, nuclear-medicine centers and other treatment settings represent 11.9%.

Hurthle Cell Carcinoma Market Geographical Analysis

North America Leads with 40.4% Market Share

North America is estimated to account for 40.4% of global Hurthle cell carcinoma market revenue in 2025, equivalent to around USD 36.4 million.

This maintains the 40.4% leadership position reported in the existing DataM Intelligence page.

The region benefits from access to experienced thyroid surgeons, molecular diagnostics, nuclear medicine, high-value TKIs and specialist cancer centers.

The United States accounts for an estimated 35.3% of global market revenue, or USD 31.8 million.

The underlying thyroid-cancer population remains substantial. SEER estimates 45,240 new U.S. thyroid cancer cases and 2,320 deaths in 2026.

The U.S. is also the principal location for the NIH-sponsored ¹⁷⁷Lu-DOTA-EB-TATE study focused specifically on metastatic RAI-resistant oncocytic/Hurthle thyroid carcinoma.

Canada represents an estimated 3.3% of global market value, around USD 3.0 million, while Mexico contributes 1.8%.

Europe Represents 27.3% of the Global Market

Europe is estimated to account for 27.3% of global Hurthle cell carcinoma treatment revenue in 2025, equal to USD 24.6 million.

GLOBOCAN recorded 77,384 new thyroid cancer cases in Europe during 2024, equivalent to around 8.1% of worldwide incidence.

Germany is modeled as Europe's largest Hurthle treatment market with 5.4% of global revenue, equal to about USD 4.9 million.

The United Kingdom accounts for 4.7%, France about 4.2%, Italy around 3.2% and Spain 2.7%.

European markets benefit from established endocrine surgery and nuclear-medicine infrastructure, but centralized reimbursement can constrain uptake of expensive systemic therapy compared with the United States.

The greater differentiation of oncocytic carcinoma in contemporary thyroid guidelines should improve treatment stratification across specialist European centers.

Asia-Pacific Is the Fastest-Growing Region

Asia-Pacific represents an estimated 23.6% of global market revenue in 2025, USD 21.2 million, and is expected to record the fastest regional growth through 2035.

The region's potential is substantially larger when measured by the overall thyroid cancer population.

Asia accounted for 742,567 of the 959,281 new thyroid cancer cases estimated worldwide in 2024, representing 77.4% of global incidence.

China is estimated to contribute 7.0% of global Hurthle cell carcinoma treatment revenue, or about USD 6.3 million in 2025, making it the largest Asia-Pacific country market.

The country's large thyroid-cancer population and expanding genomic-testing infrastructure support long-term adoption of targeted medicine.

China has also been an early market for precision thyroid therapies. The existing DMI report notes Chinese approval of selpercatinib for eligible RET fusion-positive advanced or metastatic thyroid cancer.

Japan represents an estimated 4.8% of global revenue, USD 4.3 million. Its mature hospital infrastructure, nuclear-medicine capabilities and access to TKIs support relatively high spending per advanced patient.

India accounts for 3.6%, or USD 3.2 million. The market is expanding with specialist oncology and endocrine-surgery services, although high-cost targeted therapy remains concentrated in major metropolitan hospitals.

South Korea represents 2.2%, while Australia contributes around 1.7% of global revenue.

Latin America Accounts for 4.8%

Latin America represents an estimated 4.8% of global Hurthle cell carcinoma market revenue in 2025, USD 4.3 million.

Brazil is the largest regional market, contributing an estimated 2.4% of global revenue, or around USD 2.2 million.

GLOBOCAN estimates 57,837 new thyroid cancer cases in Latin America and the Caribbean during 2024, demonstrating a meaningful underlying patient population despite considerably lower pharmaceutical revenue than North America.

Access to specialized thyroid surgery is relatively broad in major urban centers, but molecular profiling and newer targeted drugs remain less consistently available.

Middle East & Africa Represent 3.9%

Middle East & Africa account for an estimated 3.9% of global treatment revenue in 2025, equivalent to about USD 3.5 million.

Saudi Arabia and the UAE offer the strongest premium-treatment opportunities in the Middle East because of expanding tertiary hospitals and precision-oncology infrastructure.

South Africa represents an important Sub-Saharan specialist-care market.

Across lower-resource settings, limited pathological subtyping, molecular testing and access to specialist nuclear medicine can restrict both diagnosis and advanced treatment of rare oncocytic thyroid carcinoma.

Hurthle Cell Carcinoma Competitive Landscape

The Hurthle cell carcinoma competitive landscape is unusual because no large commercial portfolio is built exclusively around this rare thyroid subtype.

Instead, companies participate through treatments approved across broader differentiated thyroid cancer or molecularly defined solid tumors.

Eisai holds a central position through Lenvima. Its current U.S. label covers adults with locally recurrent or metastatic, progressive, RAI-refractory differentiated thyroid cancer.

Exelixis, together with commercial partners including Ipsen in international markets, participates through Cabometyx. FDA approval covers differentiated thyroid cancer progressing after prior VEGFR-targeted therapy in patients who are RAI refractory or ineligible for RAI.

Bayer remains relevant through Nexavar and the wider differentiated-thyroid-cancer targeted-treatment landscape. Bayer also has a precision-oncology position through the TRK inhibitor Vitrakvi, whose label was updated in April 2025 for NTRK fusion-positive solid tumors.

Eli Lilly has an important biomarker-directed position through Retevmo. Its current label includes advanced or metastatic RET fusion-positive thyroid cancer requiring systemic therapy when the disease is RAI refractory if RAI is appropriate.

Roche/Genentech participates in tumor-agnostic precision oncology through Rozlytrek for eligible NTRK fusion-positive solid tumors.

The emerging radioligand pathway introduces another category of future competitors. NIH's development of ¹⁷⁷Lu-DOTA-EB-TATE illustrates how nuclear medicine could enter Hurthle carcinoma as a dedicated treatment platform rather than merely as conventional I-131 therapy.

Company Positioning

RAI-Refractory DTC Leaders: Eisai and Exelixis hold important positions through established multikinase inhibitors used across progressive differentiated thyroid cancers.

Precision Oncology Players: Eli Lilly, Bayer and Roche provide molecularly selected treatment options for RET- or NTRK-driven tumors where eligible.

Nuclear Medicine Opportunity: Development of somatostatin-receptor-targeted radioligand therapy could create a new competitor class specifically for RAI-resistant Hurthle carcinoma.

Generic and Supportive Therapy Players: Multiple manufacturers participate through radioactive iodine, levothyroxine and other established thyroid-management medicines.

Through 2035, competitive differentiation will increasingly depend on improving efficacy after RAI failure, reducing chronic TKI toxicity and identifying biomarker-defined patient groups.

Recent Hurthle Cell Carcinoma Market Developments

• August 2026: The NIH Clinical Center updated its planned study of ¹⁷⁷Lu-DOTA-EB-TATE for metastatic, radioactive-iodine–non-responsive oncocytic/Hurthle-cell thyroid cancer. The study is not yet recruiting and represents one of the most disease-specific advanced-therapy programs in the market.
• July 2026: The American Thyroid Association highlighted the 2025 differentiated-thyroid-cancer guideline shift toward local therapy and surveillance before TKIs in suitable patients with RAI-refractory metastatic disease.
• March 2026: The ClinicalTrials.gov record for a Phase IV lenvatinib study in progressive RAI-refractory differentiated thyroid cancer was updated after completion of the study in September 2025.
• 2026: The current U.S. Retevmo label continues to cover RET fusion-positive advanced or metastatic thyroid cancer requiring systemic treatment when RAI refractory if RAI is appropriate.
• December 2025: ATA summarized the new 2025 differentiated-thyroid-cancer guidelines, which separately characterize oncocytic thyroid carcinoma and its greater resistance to radioactive iodine.
• September 2025: A real-world study reported continued activity of lenvatinib across differentiated thyroid carcinoma populations, including patients in whom RAI treatment was not feasible.
• April 2025: The U.S. prescribing information for Vitrakvi was updated for NTRK fusion-positive solid tumors, maintaining a tumor-agnostic precision-treatment pathway potentially relevant to molecularly eligible thyroid cancers.

Hurthle Cell Carcinoma Treatment Selection and Procurement Priorities

Treatment selection begins with pathological confirmation and the extent of invasion.

Hurthle tumors cannot be treated solely according to cytological appearance because malignant behavior depends substantially on capsular and vascular invasion and disease spread.

Surgical extent is therefore an important early decision. Tumor size, invasion, lymph-node involvement, distant disease and recurrence risk influence whether patients undergo lobectomy, completion thyroidectomy or total thyroidectomy.

Radioactive iodine eligibility is another key consideration. Because oncocytic carcinoma is less reliably iodine avid, clinicians increasingly need evidence that RAI is likely to deliver meaningful benefit before repeated administration.

Disease tempo matters in metastatic RAI-refractory cancer. The updated ATA approach supports local therapy or surveillance for selected slow-growing disease rather than automatic initiation of chronic systemic therapy.

Molecular profiling becomes particularly valuable before systemic therapy. RET or NTRK fusions may open access to highly selective targeted medicines.

Toxicity and quality of life influence TKI initiation and sequencing because systemic therapies may continue for long periods.

Finally, nuclear-medicine infrastructure could become more important if Hurthle-specific radioligand treatment advances through clinical development.

Strategic Opportunity Areas Through 2035

RAI-Refractory Disease

Patients whose disease no longer concentrates iodine remain the highest-value unmet clinical population.

Better treatments that avoid prolonged broad-spectrum TKI exposure could command significant interest despite the rarity of the cancer.

Hurthle-Specific Radioligand Therapy

The NIH ¹⁷⁷Lu-DOTA-EB-TATE program gives the market a concrete theranostic development pathway.

If somatostatin-receptor imaging can reliably identify candidates and treatment demonstrates durable disease control, the approach could establish a distinct radiopharmaceutical segment.

Genomic Profiling

Comprehensive molecular testing can identify rare but actionable alterations and help distinguish patients who may benefit from selective RET or TRK inhibitors.

Redifferentiation Therapy

Restoring radioactive-iodine uptake in previously RAI-refractory thyroid cancer remains an important research direction. A 2026 precision-thyroid-cancer review identifies redifferentiation strategies alongside molecularly matched treatment as an emerging approach to overcoming therapeutic resistance.

Asia-Pacific Treatment Access

Asia represents more than three-quarters of global thyroid-cancer incidence but a considerably smaller percentage of commercial Hurthle treatment revenue.

Greater pathological recognition of oncocytic carcinoma, broader genomic testing and improved access to targeted therapies could progressively close this gap.

Why Choose DataM Intelligence?

DataM Intelligence provides a disease-specific assessment of Hurthle cell carcinoma rather than treating the condition as an indistinguishable subset of follicular thyroid cancer.

The report evaluates the treatment implications of the shift toward oncocytic thyroid carcinoma terminology, updated ATA recurrence-risk assessment and greater recognition of radioactive-iodine resistance.

Its market analysis quantifies stage, treatment, end-user, regional and country-level commercial opportunities.

The report distinguishes surgery and risk-adapted RAI from the high-value systemic-treatment market involving lenvatinib, cabozantinib and molecularly selected RET/NTRK therapies.

Pipeline analysis tracks emerging disease-specific approaches, including the NIH ¹⁷⁷Lu-DOTA-EB-TATE radioligand program for metastatic RAI-non-responsive Hurthle carcinoma.

The study also identifies white-space opportunities in precision medicine, local therapy, redifferentiation and nuclear oncology.

Target Audience

Pharmaceutical and biotechnology companies, thyroid-cancer drug developers, endocrine surgeons, hospitals, comprehensive cancer centers, nuclear-medicine companies, radiopharmaceutical developers, endocrinology practices, molecular-diagnostic companies, contract research organizations, healthcare investors, licensing teams and academic thyroid-cancer research centers.